Exclusion Criteria:~1. Non-AD dementia, probable AD with Down syndrome, APP, PS-1, or PS-2 mutations (known
familial AD), LBD and Fronto-temporal dementia (FTD)~2. History of clinically significant stroke~3. Current
evidence or history in past two years of epilepsy, focal brain lesion, head injury with loss of consciousness
or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder,
alcohol or substance abuse~4. Sensory impairment that would preclude participation/cooperation with the
protocol~5. Patients with hypokalemia, hypomagnesaemia, or long QTc syndrome.~6. Concomitant drugs known to
prolong the QTc interval (>461ms) and history of cardiovascular disease, including myocardial infarction or
cardiac failure, angina, arrhythmia~7. Prescribed strong CYP3A4 inhibitors or a medical history of liver or
pancreatic disease~8. Evidence of any significant clinical disorder or laboratory finding that renders the
participant unsuitable for receiving an investigational drug including clinically significant or unstable
hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal or other
systemic disease or laboratory abnormality~9. Active neoplastic disease, history of cancer five years prior to
screening, including breast cancer (history of treated basal or squamous skin cancer, or stable prostate cancer
are not exclusionary)~10. Pregnancy or possible pregnancy~11. Contraindications to LP: prior lumbosacral spine
surgery, severe degenerative joint disease or deformity of the spine, platelets < 100,000, use of
Coumadin/warfarin, or history of a bleeding disorder~12. Contraindication to MRI~13. Evidence of more than 4
micro hemorrhages and/or hemosiderosis by a recent (12 months) and/or the screening MRI.~14. A low B12 is
exclusionary, unless follow-up labs (homocysteine (HC) and methylmalonic acid (MMA)) indicate that it is not
physiologically significant.~15. Enrolled in another active trial investigating an experimental drug or therapy
for AD~16. HIV positive
